Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonel Trebicka

Showing results (271-280 of 511) with videos related to

Pageof 52
Sort By:
European Journal of Heart Failure|July 17, 2021
Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosisMatthias Unterhuber, Karl-Patrik Kresoja, Christian Besler, et al.
The Lancet. Gastroenterology & Hepatology|February 20, 2026
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose studyFrank Erhard Uschner, Martin McCoy, Olaf Tyc, et al.
Plos One|August 25, 2021
Role of circulating angiogenin levels in portal hypertension and TIPSAlexander Queck, Frank E Uschner, Philip G Ferstl, et al.
Oncotarget|December 15, 2018
The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertensionFrank Erhard Uschner, Florian Schueller, Ivelina Nikolova, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 11, 2014
Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertensionJonel Trebicka, Cyrus Wix, Matthias von Heydebrand, et al.
The American Journal of Pathology|January 17, 2015
The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic ratsLen Verbeke, Ricard Farre, Bert Verbinnen, et al.
European Radiology|April 24, 2015
Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosisGuido M Kukuk, Kanishka Hittatiya, Alois M Sprinkart, et al.
International Journal of Molecular Sciences|May 13, 2020
Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 RatsCarla Cremonese, Robert Schierwagen, Frank Erhard Uschner, et al.
Scientific Reports|September 17, 2016
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosisLen Verbeke, Inge Mannaerts, Robert Schierwagen, et al.
Hepatology (Baltimore, Md.)|January 9, 2021
The Use of Rifaximin in Patients With CirrhosisPaolo Caraceni, Victor Vargas, Elsa Solà, et al.
Pageof 52

Showing results (271-280 of 511) with videos related to

Sort By:
Pageof 52
European Journal of Heart Failure|July 17, 2021
Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosisMatthias Unterhuber, Karl-Patrik Kresoja, Christian Besler, et al.
The Lancet. Gastroenterology & Hepatology|February 20, 2026
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose studyFrank Erhard Uschner, Martin McCoy, Olaf Tyc, et al.
Plos One|August 25, 2021
Role of circulating angiogenin levels in portal hypertension and TIPSAlexander Queck, Frank E Uschner, Philip G Ferstl, et al.
Oncotarget|December 15, 2018
The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertensionFrank Erhard Uschner, Florian Schueller, Ivelina Nikolova, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 11, 2014
Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertensionJonel Trebicka, Cyrus Wix, Matthias von Heydebrand, et al.
The American Journal of Pathology|January 17, 2015
The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic ratsLen Verbeke, Ricard Farre, Bert Verbinnen, et al.
European Radiology|April 24, 2015
Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosisGuido M Kukuk, Kanishka Hittatiya, Alois M Sprinkart, et al.
International Journal of Molecular Sciences|May 13, 2020
Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 RatsCarla Cremonese, Robert Schierwagen, Frank Erhard Uschner, et al.
Scientific Reports|September 17, 2016
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosisLen Verbeke, Inge Mannaerts, Robert Schierwagen, et al.
Hepatology (Baltimore, Md.)|January 9, 2021
The Use of Rifaximin in Patients With CirrhosisPaolo Caraceni, Victor Vargas, Elsa Solà, et al.
Pageof 52